Holen Sie sich die Stockscreener-App
1.31
1.50%
-0.02
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Lucid Cap Mkts - Defense World
INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus
Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com
INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of “Reduce” by Analysts - Defense World
Sentiment Watch: Whats the RSI of INmune Bio Inc stockBreakout Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Breakout Zone: Is INmune Bio Inc stock undervalued right nowMarket Movers & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: What is the earnings history of INmune Bio IncJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Aug Intraday: Is CRBG undervalued by DCF analysisWeekly Earnings Recap & Weekly Momentum Picks - baoquankhu1.vn
Inmune Bio (INMB): Why This Beaten-Down Small-Cap Is Back on Risk Radars - AD HOC NEWS
INMB Technical Analysis & ETF Price Forecast - Intellectia AI
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next - TipRanks
INmune Bio Highlights CORDStrom RDEB Program and IP Strength - TipRanks
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
INMB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inmune Bio, Inc. advances therapies for rare disease impact beyond skin - Traders Union
INmune Bio Announces Upcoming Webinar on New RDEB Treatment Data - National Today
INMB.O Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Decliners: What is the earnings history of INmune Bio IncJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
INmune Bio Inc. to Host Webinar on CORDStrom Treatment for Recessive Dystrophic Epidermolysis Bullosa, Highlighting New Clinical Data and Insights from MissionEB Study - Quiver Quantitative
New trial data on systemic treatment for a painful skin disease - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Aug Action: What are INmune Bio Incs earnings expectations2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
INMB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is INmune Bio Inc. stock a buy for dividend growthPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization - TipRanks
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026 - Epidermolysis Bullosa News
Inmune Bio announces FDA alignment on integrated Phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
Inmune Bio announces FDA alignment on integrated phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? - Asianet Newsable
INmune Bio Gains FDA Alignment On Phase 2b/3 Trial Design For Alzheimer's Drug XPro1595 - Nasdaq
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - The Manila Times
Will INmune Bio Inc. benefit from geopolitical trends2025 Market Outlook & Daily Growth Stock Investment Tips - mfd.ru
Is INmune Bio Inc. stock a value trapRate Hike & Safe Entry Momentum Tips - mfd.ru
INmune Bio submits pre-submission package for CORDStrom with MHRA - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of “Reduce” by Brokerages - Defense World
Inmune Bio Inc Submitted Pre-Submission Package For Cordstrom With Uk's Mhra - TradingView
Inmune Bio Advances Cordstrom™ Towards Uk Marketing Authorization In Rdeb - TradingView
INmune Bio (INMB) Advances with Regulatory Submission for CORDSt - GuruFocus
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - The Manila Times
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):